Skip to main content
Premium Trial:

Request an Annual Quote

PerkinElmer to Realign Business Groups to Focus on Human, Environmental Health

NEW YORK (GenomeWeb News) – PerkinElmer announced after market close today that it will realign its business units as of Jan. 1, 2009, to focus on human and environmental health.
PerkinElmer’s operations are currently organized into two main divisions: Life and Analytical Sciences and Optoelectronics. Under the new model, the company’s operations will be split between two new businesses: Human Health and Environmental Health.
The Human Health business will develop diagnostics, tools, and applications for biomedical research and drug discovery. This business will include the company’s Genetic Screening, Bio-discovery, and Medical Imaging operating units. Robert Friel, PerkinElmer’s president and CEO, will lead the Human Health business on an interim basis.
The Environmental Health business will be focused on product safety and energy efficiency. It will include the company’s Analytical Sciences, Laboratory Services, and Detection and Illumination (formerly known as Sensors and Specialty Lighting) operating units. John Roush, who currently leads the company’s Optoelectronics business, will lead this division.
In line with the restructuring, PerkinElmer said it has placed “a portion” of its specialty lighting business, which includes xenon flashtubes, ceramic xenon light sources, intense pulsed light, laser pump sources, and LEDs, under strategic review.
The company said that the businesses under review are expected to generate around $90 million in revenue for 2008.
PerkinElmer does not break out revenues for its product lines, but the Optoelectronics segment that houses the specialty lighting business generated total sales of $460.1 million in fiscal 2007, while the company's total revenues for the year were $1.79 billion.

The Scan

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.

Study Explores Animated Digital Message Approach to Communicate Genetic Test Results to Family Members

In the Journal of Genetic Counseling, the approach showed promise in participants presented with a hypothetical scenario related to a familial hereditary breast and ovarian cancer syndrome diagnosis.

Computational Tool Predicts Mammalian Messenger RNA Degradation Rates

A tool called Saluki, trained with mouse and human messenger RNA data, appears to improve mRNA half-life predictions by taking RNA and genetic features into account, a Genome Biology paper reports.

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.